scholarly journals Accounting for symptom heterogeneity can improve neuroimaging models of antidepressant response after electroconvulsive therapy

2021 ◽  
Author(s):  
Benjamin S. C. Wade ◽  
Gerhard Hellemann ◽  
Randall T. Espinoza ◽  
Roger P. Woods ◽  
Shantanu H. Joshi ◽  
...  
Author(s):  
Frederick Cassidy ◽  
Richard D. Weiner ◽  
Thomas B. Cooper ◽  
Bernard J. Carroll

2010 ◽  
Vol 196 (6) ◽  
pp. 493-494 ◽  
Author(s):  
Frederick Cassidy ◽  
Richard D. Weiner ◽  
Thomas B. Cooper ◽  
Bernard J. Carroll

SummaryThe mechanism of action of electroconvulsive therapy (ECT) in treating major depression is unknown. We studied two candidate mechanisms through inhibiting simultaneously the synthesis of noradrenaline and serotonin in patients immediately after successful treatment with ECT using a randomised, placebo-controlled, double-blind crossover design. There were no significant changes in depression scores under any experimental conditions, or between the amine-depleted and placebo groups despite reductions of 61% in serum homovanillic acid, 47% in 3-methoxy-4-hydroxyenylethyleneglycol, and 89% in serum tryptophan. Catecholamine and serotonin availability may not be necessary for maintaining the initial antidepressant response to ECT.


Author(s):  
Amber M. Leaver ◽  
Megha Vasavada ◽  
Antoni Kubicki ◽  
Benjamin Wade ◽  
Joana Loureiro ◽  
...  

2019 ◽  
Vol 85 (10) ◽  
pp. S124
Author(s):  
Amber Leaver ◽  
Megha Vasavada ◽  
Antoni Kubicki ◽  
Benjamin Wade ◽  
Gerhard Hellemann ◽  
...  

PeerJ ◽  
2021 ◽  
Vol 9 ◽  
pp. e10699
Author(s):  
Wei Zheng ◽  
Qiaomei Cen ◽  
Sha Nie ◽  
Minyi Li ◽  
Rong Zeng ◽  
...  

Objective To firstly examine the relationship between serum brain-derived neurotrophic factor (BDNF) levels and antidepressant response to ketamine as an anaesthesia in electroconvulsive therapy (ECT) in Chinese patients with treatment-refractory depression (TRD). Methods Thirty patients with TRD were enrolled and underwent eight ECT sessions with ketamine anaesthesia (0.8 mg/kg) alone. Depression severity, response and remission were evaluated using the 17-item Hamilton Depression Rating Scale (HAMD-17). Enzyme-linked immunosorbent assay (ELISA) was applied to examine serum BDNF levels in patients with TRD at baseline and after the second, fourth and eighth ECT sessions. Baseline serum samples were also collected for 30 healthy controls. Results No significant differences were observed in serum BDNF levels between patients with TRD and healthy controls at baseline (p > 0.05). The remission rate was 76.7% (23/30) after the last ECT treatment, although all patients with TRD obtained antidepressant response criteria. Serum BDNF levels were not altered compared to baseline, even between remitters and nonremitters (all p > 0.05), despite the significant reduction in HAMD-17 and Brief Psychiatric Rating Scale (BPRS) scores after ECT with ketamine anaesthesia (all p < 0.05). The antidepressant effects of ECT with ketamine anaesthesia were not correlated with changes in serum BDNF levels (all p > 0.05). Conclusion This preliminary study indicated that serum BDNF levels do not appear to be a reliable biomarker to determine the antidepressant effects of ketamine as an anaesthesia in ECT for patients with TRD. Further studies with larger sample sizes are warranted to confirm these findings.


2019 ◽  
Vol 85 (6) ◽  
pp. 466-476 ◽  
Author(s):  
Amber M. Leaver ◽  
Megha Vasavada ◽  
Shantanu H. Joshi ◽  
Benjamin Wade ◽  
Roger P. Woods ◽  
...  

2019 ◽  
Vol 85 (10) ◽  
pp. S67
Author(s):  
Benjamin Wade ◽  
Gerhard Hellemann ◽  
Randall Espinoza ◽  
Roger Woods ◽  
Shantanu Joshi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document